EpiCord Expandable Placental Allograft Is Launched by MiMedx

September 14, 2020

EpiCord Expandable Placental Allograft has been launched. The news was announced today by MiMedx.

EpiCord Expandable Placental Allograft allows the allograft to cover up to twice the surface area once expanded. This new placental tissue allograft provides healthcare professionals an additional option to support the advanced wound care needs of their patients with larger, chronic, and hard-to-heal wounds.

“There is growing demand for advanced interventions in the treatment of chronic wounds,” said Dr. Bill Tettelbach, MiMedx Principal Medical Officer. “Many are unaware that about 20 percent of moderate-to-severe diabetic foot ulcers lead to amputation. When people with diabetes have a non-traumatic below the knee amputation, their mortality rate can exceed 70 percent at five years. Treatment of these patients is aimed at healing the wound, saving their limb and improving their quality of life. Healthcare professionals are looking for added versatility when addressing larger, hard-to-heal wounds, and the new EpiCord Expandable provides a versatile and flexible option to help meet this urgent patient need for those who may require specific interventions to restart the healing process.”

More than 30 million Americans are living with diabetes and the numbers continue to increase. Of those with diabetes, 2.9 million of them suffer from chronic wounds. Data show that the cost of treating chronic wounds in the United States is rising sharply, exceeding an estimated $28 billion annually.

Timothy R. Wright, MiMedx Chief Executive Officer, commented, “As a pioneer in the development of placental tissue technology, MiMedx is constantly improving our knowledge of placental science – as a unique biological system that supports growth and healing – to elevate the standard of care and help bring hope and relief to the millions suffering with chronic and hard-to-heal wounds. With an aging population and rapidly growing number of people with diabetes, new applications of placental-tissue science like EpiCord Expandable will help to meet public health needs and advance the field.”

SourceMiMedx

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution